Book Value per Share: ymabs.com (YMAB)

Public company logo of Y-mAbs Therapeutics Inc (YMAB)

The share price history of Y-mAbs Therapeutics (YMAB) clearly demonstrates the dynamics of a business developing antibodies to combat rare tumors, where the platform's versatility minimizes regulatory risks. Thomas Gaad's team effectively brings scientific developments to the global market. The drug Danyelza provides a steady cash flow, with metrics currently at 1.93, supporting high operating profit driven by niche demand.

Y-mAbs Therapeutics Inc (YMAB) - Accounting Value per Share from 07/04/2022 to 09/27/2025

Summary analytical data breakdowns for ymabs.com (YMAB)

- price and consensus price forecast:
Stock Price YmAbs|YMAB - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Y-mAbs Therapeutics, Inc.|YMAB - Total Company Value
- book capitalization data:
Book Value per Share Y-mAbs Therapeutics|YMAB - Company Net Assets|Market Capitalization to Book Value Ratio ymabs.com|YMAB - Company Total Assets
- debt and liquidity data:
Debt to Equity Y-mAbs Therapeutics|YMAB - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Y-mAbs Therapeutics, Inc.|YMAB - Company Total Debt|Debts to Book Capitalization Y-mAbs Therapeutics, Inc.
Analysis of all company metrics:YmAbs, YMAB
Manufactured product of ymabs.com

Investors utilize capital multiples to verify an issuer's financial stability and assess the real value of its assets. An analysis of the IFRS book value per share demonstrates the proportion of net assets per security, which for the non-cyclical pediatric oncology business of Y-mAbs Therapeutics (YMAB) serves as an indicator of the efficiency of R&D capitalization and the expansion of market presence across critical medical segments.

Competitor analysis for Y-mAbs Therapeutics

BeiGene Corp - Book Value per Share|HALO - Book Value per Share|Revolution Medicines (RVMD) - Book Value per Share|ascentage.com (AAPG) - Net Assets per Single Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|AURA: Book Value per Share|CADL - Accounting Value per Share|Book Value per Share ARAY|SLS (SELLAS Life Sciences Group) - Net Asset Value per Share|ACTU - Net Assets per Single Share|Accounting Value of a Share citiusonc.com (CTOR)|TuHURA Biosciences, Inc. (HURA) - Accounting Value per Share|Accounting Value of a Share Protara Therapeutics Inc (TARA)|Fate Therapeutics Corp - Book Value per Share|WHWK - Accounting Value per Share|TScan - Accounting Value per Share|CSBR: Book Value per Share|Net Assets per Single Share xbiotech.com XBIT|CEL-SCI (CVM) - Accounting Value of a Share|Book Value per Share OSTX (OS Therapies Inc)|Net Asset Value per Share radiopharmtheranostics.com (RADX)|Artiva Biotherapeutics, Inc. - Accounting Value per Share|Net Asset Value per Share adlainortye.com ANL|VERU (Veru) - Accounting Value per Share|Tempest Therapeutics Inc - Book Value of One Share|XLO: Net Assets per Single Share|RENB - Accounting Value per Share|MURA: Book Value per Share|Kairos Pharma (KAPA) - Book Value per Share|Book Value per Share OnKure Therapeutics, Inc.|Net Assets per Single Share GDTC|CRIS (Curis, Inc.) - Net Assets per Single Share|Net Assets per Share apollomicsinc.com APLM|Accounting Value per Share Tharimmune, Inc.|ADVB - Accounting Value of a Share|Accounting Value per Share Genprex GNPX|CLDI - Book Price of a Share|Book Value per Share Sunshine Biopharma, Inc. SBFM|Xenetic Biosciences, Inc. (XBIO) - Accounting Value of a Share|Book Value per Share SLRX (Salarius Pharmaceuticals)|Net Asset Value per Share PPBT|American Oncology Network (AONC) - Net Assets per Single Share|Accounting Value of a Share BeiGene Ltd. (BGNE)|Book Value per Share CKPT (Checkpoint Therapeutics, Inc)|elevationoncology.com - Book Value per Share|Net Assets per Single Share iCAD Corp|IKNA - Share Book Value|Book Value per Share NTBL|Net Asset Value per Share Viracta Therapeutics, Inc.|MOR (MorphoSys Corp) - Accounting Value per Share|Book Value per Share NAYA Biosciences Corp (NAYA)|Accounting Value per Share Ascentage Pharma Group